SG11202100185VA - Treating ulcerative colitis with brazikumab - Google Patents
Treating ulcerative colitis with brazikumabInfo
- Publication number
- SG11202100185VA SG11202100185VA SG11202100185VA SG11202100185VA SG11202100185VA SG 11202100185V A SG11202100185V A SG 11202100185VA SG 11202100185V A SG11202100185V A SG 11202100185VA SG 11202100185V A SG11202100185V A SG 11202100185VA SG 11202100185V A SG11202100185V A SG 11202100185VA
- Authority
- SG
- Singapore
- Prior art keywords
- brazikumab
- ulcerative colitis
- treating ulcerative
- treating
- colitis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862697939P | 2018-07-13 | 2018-07-13 | |
| PCT/IB2019/000720 WO2020012244A2 (en) | 2018-07-13 | 2019-07-11 | Treating ulcerative colitis with brazikumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100185VA true SG11202100185VA (en) | 2021-02-25 |
Family
ID=68072845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100185VA SG11202100185VA (en) | 2018-07-13 | 2019-07-11 | Treating ulcerative colitis with brazikumab |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210277105A1 (en) |
| EP (1) | EP3820897A2 (en) |
| JP (1) | JP2021532176A (en) |
| KR (1) | KR20210032441A (en) |
| CN (1) | CN112689643A (en) |
| AU (1) | AU2019300491A1 (en) |
| CA (1) | CA3105598A1 (en) |
| EA (1) | EA202190197A1 (en) |
| IL (1) | IL279917A (en) |
| SG (1) | SG11202100185VA (en) |
| WO (1) | WO2020012244A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112807428A (en) * | 2020-06-12 | 2021-05-18 | 江苏荃信生物医药有限公司 | Pharmaceutical composition comprising anti-human interleukin 23 monoclonal antibody |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| PE20000183A1 (en) | 1997-07-25 | 2000-03-11 | Schering Corp | MAMMAL CYTOKINES AND RELATED REAGENTS |
| PT1896073E (en) | 2005-06-30 | 2013-05-28 | Janssen Biotech Inc | Anti-il-23 antibodies, compositions, methods and uses |
| PT1937721E (en) | 2005-08-25 | 2010-09-17 | Lilly Co Eli | Anti-il-23 antibodies |
| RS55788B1 (en) | 2005-08-31 | 2017-08-31 | Merck Sharp & Dohme | Engineered anti-il-23 antibodies |
| MX2008008621A (en) | 2005-12-29 | 2008-11-27 | Centocor Inc | Human anti-il-23 antibodies, compositions, methods and uses. |
| AU2007260787A1 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc | IL-17 and IL-23 antagonists and methods of using the same |
| WO2008103473A1 (en) | 2007-02-23 | 2008-08-28 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| RS52345B (en) | 2007-02-23 | 2012-12-31 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| AR068723A1 (en) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | PROTEIN THAT JOINS ANTIGENS THAT JOINS HUMAN IL-23 AND ITS USES |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| MX2011002159A (en) | 2008-08-27 | 2011-03-29 | Schering Corp | Lyophilized formulatons of engineered anti-il-23p19 antibodies. |
| JP2012522749A (en) | 2009-04-01 | 2012-09-27 | グラクソ グループ リミテッド | Anti-IL-23 immunoglobulin |
| WO2010142534A1 (en) | 2009-05-27 | 2010-12-16 | Ablynx Nv | Biparatopic protein constructs directed against il-23 |
| JO3244B1 (en) * | 2009-10-26 | 2018-03-08 | Amgen Inc | Human il-23 antigen binding proteins |
| LT2523688T (en) | 2010-01-15 | 2018-03-12 | Kirin-Amgen, Inc. | Antibody formulation and therapeutic regimens |
| CA2805653A1 (en) | 2010-07-20 | 2012-01-26 | Cephalon Australia Pty Ltd | Anti-il-23 heterodimer specific antibodies |
| MX343858B (en) | 2010-11-04 | 2016-11-25 | Boehringer Ingelheim Int | Anti-il-23 antibodies. |
| US20160031983A1 (en) * | 2013-03-15 | 2016-02-04 | Amgen Inc. | Methods for treating crohn's disease using an anti-il23 antibody |
-
2019
- 2019-07-11 CA CA3105598A patent/CA3105598A1/en active Pending
- 2019-07-11 CN CN201980046566.9A patent/CN112689643A/en active Pending
- 2019-07-11 AU AU2019300491A patent/AU2019300491A1/en active Pending
- 2019-07-11 JP JP2021524129A patent/JP2021532176A/en active Pending
- 2019-07-11 WO PCT/IB2019/000720 patent/WO2020012244A2/en unknown
- 2019-07-11 US US17/259,448 patent/US20210277105A1/en active Pending
- 2019-07-11 EP EP19779090.0A patent/EP3820897A2/en active Pending
- 2019-07-11 EA EA202190197A patent/EA202190197A1/en unknown
- 2019-07-11 SG SG11202100185VA patent/SG11202100185VA/en unknown
- 2019-07-11 KR KR1020217004216A patent/KR20210032441A/en unknown
-
2021
- 2021-01-03 IL IL279917A patent/IL279917A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA202190197A1 (en) | 2021-04-26 |
| US20210277105A1 (en) | 2021-09-09 |
| CN112689643A (en) | 2021-04-20 |
| WO2020012244A2 (en) | 2020-01-16 |
| AU2019300491A1 (en) | 2021-03-04 |
| WO2020012244A3 (en) | 2020-06-04 |
| CA3105598A1 (en) | 2020-01-16 |
| KR20210032441A (en) | 2021-03-24 |
| IL279917A (en) | 2021-03-01 |
| JP2021532176A (en) | 2021-11-25 |
| EP3820897A2 (en) | 2021-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL256279A (en) | Crispr/cas9-based treatments | |
| PT3552652T (en) | Catheter devices with valves | |
| GB202009845D0 (en) | Flood vent with panel | |
| IL277514A (en) | Methods of treating ulcerative colitis | |
| GB201608885D0 (en) | Treatment | |
| HK1252692A1 (en) | Methods of treating or preventing a proteopathy | |
| IL275553A (en) | Surfboard with overlap | |
| IL272738A (en) | Treatment regimens | |
| HK1250626A1 (en) | Combination treatments with seribantumab | |
| GB201702272D0 (en) | Water treatment | |
| IL279917A (en) | Treating ulcerative colitis with brazikumab | |
| IL266292A (en) | Treatment regimens | |
| EP3741368A4 (en) | Capsule for treating ulcerative colitis | |
| EP3307220A4 (en) | Belt with treated inner surface | |
| GB2556870B (en) | Flood Prevention | |
| ZAA201801111S (en) | Baths | |
| ZAA201801118S (en) | Baths | |
| GB201814818D0 (en) | Treatment Regimen | |
| GB201820215D0 (en) | Treatments etc | |
| ZA201804726B (en) | Water treatment facility | |
| HK1243578A1 (en) | Radiological equipment with adaptive control | |
| ZA201706977B (en) | Water treatment | |
| GB201722126D0 (en) | Jacuzzis / baths | |
| GB201708860D0 (en) | ZoneFeeder with zoneLock | |
| PT3239415T (en) | Tap with case |